Back to Search Start Over

Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats.

Authors :
El-Nabarawy NA
Teaima MH
Helal DA
Source :
Drug design, development and therapy [Drug Des Devel Ther] 2019 Nov 21; Vol. 13, pp. 3929-3937. Date of Electronic Publication: 2019 Nov 21 (Print Publication: 2019).
Publication Year :
2019

Abstract

Objective: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%).<br />Materials and Methods: A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally.<br />Results: We found decreased T <subscript>max</subscript> , increased C <subscript>max</subscript> , AUC <subscript>0-6</subscript> , AUC <subscript>0-∞ and</subscript> ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan.<br />Conclusion: Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment.<br />Competing Interests: The authors declare that they have no competing interests in this work.<br /> (© 2019 El-Nabarawy et al.)

Details

Language :
English
ISSN :
1177-8881
Volume :
13
Database :
MEDLINE
Journal :
Drug design, development and therapy
Publication Type :
Academic Journal
Accession number :
31819367
Full Text :
https://doi.org/10.2147/DDDT.S220473